All News

ACRmtg.jpg (keep)

Industry Abstract Previews - ACR2020

Jack Cush, MD

Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies for you to review and evaluate as part of your to-do list.

Read Article
COVID.Flu_.Virus_.jpg (keep)

Infection and Rheumatic Diseases: A New Dawn

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA

Infection in the setting of autoimmune rheumatic disease (ARD) has been the subject of increasing research and clinical interest for decades. Despite the huge burden of infection in patients with ARDs, this area of research has really been catapulted to the centre-stage of research agendas and coverage at congresses, including ACR 2020, with the arrival of the coronavirus disease 2019 (COVID-19) pandemic.

Read Article
ACR20 Podcast

QD Clinic Podcast - 106 thru 109

Jack Cush, MD

Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage.



In this compilation from the past week we talk about



- HIV and arthritis



- Hyperuricemia in PsA



- An odd kind of dermatomyositis

Read Article
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by BMS, @HorizonNews , @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

How well do your RA patients sleep? Is OSA an issue? Validated questionnaires and clinician questioning missed two-thirds (23/35) of mod-severe OSA, no clues from steroid use or RA disease activity. Should we be screening more patients? @UCSFHospitals #ACR20 ABST0196 @RheumNow https://t.co/kibwDPYYn9
David Liew drdavidliew ( View Tweet)
Abst#0138 at #ACR20 shows the importance of identifying alignments & discordances in perceptions of RA tx between providers & patients, individualizing txs accordingly, & a need to engage in shared-decision making to optimize RA care. @RheumNow https://t.co/dTj0S7Zm5x
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
DVT/PE has been the sticking point for baricitinib in RA. DVT/PE risk in integrated safety analysis >8y: incidence doesn't increase, but also doesn't decrease. No diff with dose either. Every drug has pros/cons; it's how we manage risk that counts... #ACR20 ABST0202 @RheumNow https://t.co/V88tQjcXSJ
David Liew drdavidliew ( View Tweet)
Data from the #ACR #RISE registry- 83,000 patients. Significant disparities in RA functional scores in Low SES, and got worse over time. ABS#0046 @RheumNow #ACR20 https://t.co/rcVb1gU250
Bella Mehta bella_mehta ( View Tweet)
Vaccinate your pts against pneumococcal- it works! 595 vaccinated pts with RA & SpA vs 2379 nonvaccinated followed to 10 yrs showed 50% less pneumonia if vaccinated even though those pts had more infections prior. Limitation not RCT & not vaccine I use @RheumNow @CRASCRRheum https://t.co/SySEL19Gcn
Janet Pope Janetbirdope ( View Tweet)
Dr Fernandez-Diaz on abatacept in RA-ILD in 263 patients. Abatacept appears safe and effective. Equivalent to RTX. Good option as s/c admin @rheumnow #ACR20 Abstr#0233 #ACRbest https://t.co/LfjqZpnGCh
Richard Conway RichardPAConway ( View Tweet)
When prescribing hydroxychloroquine for RA, SLE, or other rheumatic diseases, do you routinely order an EKG (either before or during)? #ACR20 @RheumNow

David Liew drdavidliew ( View Tweet)

Dr Choi et al case control study of methotrexate in RA. No increased risk of NAFLD seen. Increased trigs and BMI associated NAFLD @rheumnow #ACR20 Abstr#0181 https://t.co/WLPuf6Ga1D
Richard Conway RichardPAConway ( View Tweet)
Using #MachineLearning, multimorbidity patterns predominant for #rheumatoid arthritis: cardiometabolic, cardiopulmonary & #Mentalhealth/pain disorders. Patterns similar to non-RA pts but prevalence higher in RA pts. @RheumNow #ACR20 abstr#0179 https://t.co/zfCxzKquDV
sheila RHEUMarampa ( View Tweet)
Even in early RA, there’s pain – and then there’s pain. Non-articular pain common very common in early RA (even at 12m) and a/w worse outcomes. Early RA isn't just about the inflammation: understand/treat the cause(s) of pain! from CATCH @earlyarthritis #ACR20 ABST0187 @RheumNow https://t.co/kR4waqHUnm
David Liew drdavidliew ( View Tweet)
Association of Hydroxychloroquine Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis https://t.co/3PrWlIGnB8 #RA #HCO #NASH - HCO decreases fatty liver

Links:

Peter Nash drpnash ( View Tweet)

Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study https://t.co/NDk0LH5Kk6 #RA #lymphoma risk driven by increased disease activity

Links:

Peter Nash drpnash ( View Tweet)

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis https://t.co/i456zSn6Ba #RA #Baricitinib #safety 13000 pt/yrs 8.4 yrs F/U no new safety signals VTE 0.5/100 pt yrs

Links:

Peter Nash drpnash ( View Tweet)

Do you plan to do a skin exam in your RA patients on MTX given new toxicity signal of skin cancer based on CIRT with NNH of 167? @JYazdanyMD #ACR20 Year in Review @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06

Links:

American College of Rheumatology ACRheum ( View Tweet)

Association Between Changes in Pain Sensitization and Changes in Disease Activity After 12 Weeks of Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis https://t.co/DLGFcDqrus #RA #pain Pain sensitization a management issue - disease control minor benefit

Links:

Peter Nash drpnash ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×